Leonard Lothstein*, Judith Soberman†, Deanna Parke*, Jatin Gandhi*, Trevor Sweatman‡, Tiffany Seagroves*
Oncology Research, Vol.28, No.5, pp. 451-465, 2020, DOI:10.3727/096504020X15898794315356
Abstract Triple-negative breast cancer (TNBC) is unresponsive to antiestrogen and anti-HER2 therapies, requiring the
use of cytotoxic drug combinations of anthracyclines, taxanes, cyclophosphamide, and platinum compounds.
Multidrug therapies achieve pathological cure rates of only 20–40%, a consequence of drug resistance and
cumulative dose limitations necessitated by the reversible cardiotoxic effects of drug therapy. Safer and more
effective treatments for TNBC are required to achieve durable therapeutic responses. This study describes the
mechanistic analyses of the novel anthracycline, pivarubicin, and its in vivo efficacy against human primary
TNBC. Pivarubicin directly activates PKCd, triggers rapid mitochondrial-dependent apoptosis, and circumvents resistance conferred by overexpression… More >
Login
Register
